Cardiovascular

Across 65 cardiovascular guidelines with nearly 7500 specific recommendations published 2012-2022, only 170 recommendations directly incorporated shared decision-making.

After 16 weeks on placebo, patients in the control group were invited to start mavacamten alongside the treatment group, explained Milind Desai, MD, MBA, director of the Hypertrophic Cardiomyopathy Center and vice chair of education at the Heart, Vascular & Thoracic Institute, Cleveland Clinic.

The authors found shifting patterns in the effects of obesity, alcohol, and smoking on atrial fibrillation.

Investigators conducted this subanalysis among patients aged 20 to 27 years, using data from the National Growth and Health Study to determine potential racial differences in left ventricular mass among female patients with obesity.

The decrease in e-cigarette use between 2014 and 2019 may be linked to improved education on the harms of the devices, while the increase in 2019 could be attributed to worsened psychological burden during the COVID-19 pandemic.

The Panicos are on a mission to change how we think about gout. Why? As a husband-and-wife DO duo, the Panicos each have a unique perspective on gout and how physicians in their respective fields can better collaborate to help patients who live with this systemic disease.

Stephen Nicholls, PhD, MBBS, Monash University and Victorian Heart Hospital, explains how he works closely with patients and study sites in SURPASS-CVOT to avoid weight loss drug discontinuation and weight regain.

New research shows that in vitro fertilization with or without intracytoplasmic sperm injection and the use of fresh or frozen embryo transfers were not associated with an increased risk of cardiovascular disease (CVD) for the mother.

Postpartum cardiovascular health counseling dropped slightly from 2016 to 2020, both for individuals with and without cardiovascular disease risk factors.

G.B. John Mancini, MD, University of British Columbia, goes into detail about the recruitment process of the VICTORION-2-PREVENT trial, which focuses on inclisiran to reduce cardiovascular risk.

Stephen Nicholls, PhD, MBBS, Monash University and Victorian Heart Hospital, expands on the patient characteristics and potential impacts of COVID-19 on SURPASS-CVOT, the phase 3 cardiovascular outcomes trial for tirzepatide.

Among people living with HIV receiving antiretroviral therapy, those taking 4-mg pitavastatin daily were 35% less likely than those taking placebo to experience a major cardiovascular event over 5 years of follow-up.

The ASPC Congress on CVD Prevention is taking place in Arlington, Texas, July 21-23. Here, G.B. John Mancini, MD, University of British Columbia, emphasizes the importance of having an international perspective on preventive cardiology.

After replicating the PURE study, researchers found that individuals with higher PURE diet scores had lower risk of death, cardiovascular disease, myocardial infarction, and stroke.

Research suggests that intense physical activity concentrated within 1-2 days and activity more evenly distributed activity across several days are associated with similarly lower risk of cardiovascular outcomes.

The FDA has approved the first over the counter (OTC) birth control pill Thursday; the US Chamber of Commerce has filed a motion for preliminary injunction on the Medicare Drug Price Negotiation program; individuals living in historically redlined areas are likely to have worse heart health.

Research was conducted by multiple laboratories in the Global Diagnostics Network and included more than 460 million lipid test results from 17 countries to determine risk of cardiovascular disease (CVD).

Erin Michos, MD, MHS, opens a discussion surrounding the utilization of bempedoic acid for patients with intolerance to statin-based therapies.

An increased risk of developing myocardial infarction was observed among patients with hidradenitis suppurativa (HS), whereas risk of cerebrovascular accident and peripheral vascular disease was comparable between those with HS and controls.

Dr Slipczuk concludes our discussion by detailing healthcare disparities commonly seen within ASCVD treatment.

A cardiology expert considers the future of lipid management within health systems and ways they can improve engagement from all parties.

Dr Slipczuk explores quality metrics, elaborating on ways to improve and align them with the latest cardiology treatment guidelines and payer considerations.

Dr Slipczuk offers strategies for sharing information and guiding appropriate ASCVD treatment both within and outside closed health systems.

Leandro N. Slipczuk, MD, PhD, details his organization’s effort to support uptake of PCSK9 inhibitors in the inpatient setting.

Dr Leandro N. Slipczuk highlights the importance of cardiovascular treatment guidelines when deciding on patient care for those with ASCVD.